Erfindergemeinschaft UroPep GbR v. Eli Lilly and Company et al, No. 2:15-cv-01202 (E.D. Tex. July 18, 2017)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Before the Court is the motion of plaintiff Erfindergemeinschaft UroPep GbR (“UroPep”) for ongoing royal ties in this case. Dkt. No. 363. Defendant Eli Lilly & Co. (“Lilly”) opposes. The Court GRANTS IN PART UroPep’s motion for royalties for the period between April 17, 2017, and July 9, 2017. BACKGROUND I n its complaint, UroPep alleged that Lilly infringed UroPep’s patent, U.S. Patent No. 8,791,124 (“the ’124 patent”), by marketing the drug Cialis for the treatment of benign prostatic hyperplasia (“BPH”).